G.P. Ellis (3).Pdf

Total Page:16

File Type:pdf, Size:1020Kb

G.P. Ellis (3).Pdf Progress in Medicinal Chemistry 16 This Page Intentionally Left Blank Progress in Medicinal Chemistry 16 Edited by G.P. ELLIS, D.SC., PH.D.,F.R.I.C. Department of Chemistry, University of Wales Institute of Science and Technology, King Edward VII Avenue, Card& CFl 3NU and G.B. WEST, B.PHARM., D.SC., PH.D., F.I.BIOL. Department of Paramedical Sciences, North East London Polytechnic, Romford Road, London El5 4LZ 1979 NORTH-HOLLAND PUBLISHING COMPANY AMSTERDAM.NEW YORK.OXFORD 0Elsevier/North-Holland Biomedical Press - 1979 AN rights reserved. No part of this publication may be reproduced, stored in a retrieval system. or transmitted in any form or by any means, electronic. mechanical, photocopying, recording or otherwise, without the prior permission of the copyright owner. ISBN for the series: 0 7204 7400 0 ISBN for this volume: 0 7204 0667 6 PUBLISHERS : Elsevier North-Holland Biomedical Press 335 Jan van Galenstraat, P.O. Box 21 1 Amsterdam, The Netherlands SOLE DISTRIBUTORS FOR THE U.S.A. AND CANADA: Elsevier/North-Holland Inc. 52 Vanderbilt Avenue New York, N.Y. 10017, U.S.A. LIBRARY OF CONGRESS CATALOGING IN PUBLICATION DATA Main entry under title: Progress in medicinal chemistry. London, Butterworths, 1961-1973 (Vols. 1-9). Amsterdam, North-Holland Publishing Co., 1974- (Vols. 10- ). Editors: 1961- G.P. Ellis and G.B. West. Includes bibliography. 1. Pharmacology-Collected works. 2. Chemistry, Medical and Pharmaceutical. I. Ellis, Gwynn Pennant, ed. 11. West, Geoffrey Buckle, 1961- ed. 111. Title: Medicinal chemistry. RS402.P78 615'.19 62-27 12 Photosetting by Thornson Press (India) Limited, New Delhi Printed in The Netherlands Preface We have pleasure in presenting five reviews in this volume. Recent trends towards international conformity in patent law are now beginning to show material benefits. The significance of these changes for medicinal chemists is outlined in Chapter 1. Steroids containing hetero atoms have been extensively studied in recent years and their synthesis and biological activity are described in Chapter 2, which is a longer review than is usual in this Series. The fight against neoplastic diseases continues to be waged on many fronts and one of these - with drugs which exhibit non-bonded interactions with nucleic acids - is surveyed in Chapter 3. The role of membranes in chemotherapy is well-established and Chapter 4 covers the inhibition by drugs of adenosine triphosphatase from microbial membranes. Finally, Chapter 5 assesses the progress made recently in our understanding of neuromuscular blockade at the cholinergic receptor. Much effort is required to prepare reviews of this type and we are indebted to our authors for their diligence and punctuality. Owners of copyright material have freely given their permission for it to be reproduced in this volume and we are grateful to them. As usual, the staff of our publishers have given us their full co-operation and it is a pleasure to acknowledge their contribution. November 1978 G.P. Ellis G.B. West This Page Intentionally Left Blank Contents Preface V 1. Recent Changes in Patent Law 1 F. Murphy, B.Sc., M.R.I.C., C.P.A., E.P.A. Fisons Ltd., Ipswich, Suffolk IPI IQH, England 2. Heterosteroids and Drug Research 35 H. Singh, M.Pharm., Ph.D., V.K. Kapoor, M.Pharm., Ph.D. and D. Paul, M.Pharm., Ph.D. Department of Pharmaceutical Sciences, Panjab University, Chandigarh 160014, India 3. The Molecular Basis for the Action of Some DNA-Binding Drugs 151 S. Neidle, B.Sc., Ph.D. Department of Biophysics, University of London King’s college, 26-29 Drury Lane, London WC2B 5RL, England 4. Inhibitors of Enzymes of Microbial Membranes; Agents Affecting MgZC-Activated Adenosine Triphosphatase 223 S.M. Hammond, B.Sc., Ph.D. Department of Biological Sciences, Purdue University, W.Lufayette, Indiana 47907, U.S.A. 5. Molecular Interactions at the Cholinergic Receptor in Neuro- muscular Blockade 257 J.B. Stenlake, D.Sc., Ph.D., C.Chem., F.P.S., F.R.I.C., F.R.S.E. Department of Pharmaceutical Chemistry, University of Strathclyde, Glasgow GI IXW, Scotland Index 287 vii This Page Intentionally Left Blank Contents of earlier volumes VOLUME 8 1 ORGANOPHOSPHORUS PESTICIDES : PHARMACOLOGY-Ian L. Natoff 2 THE MODE OF ACTION OF NOVOBIOCIN-A. Morris and A.D. Russell 3 SOME PYRIMIDINES OF BIOLOGICAL AND MEDICINAL INTEREST-Part 111-C. C. Cheng and Barbara Roth 4 ANTIVIRAL AGENTS-D.L. Swallow 5 ANTIFERTILITY AGENTS-V. Petrow 6 RECENT ADVANCES IN THE CHEMOTHERAPY OF MALARIA-R.M. Pinder 7 THE PROSTAGLANDINS-M.P.L. Caton VOLUME 9 1 NATURALLY-OCCURRING ANTITUMOUR AGENTS-K. Jewers, A.H. Machanda and Mrs. H.M. Rose 2 CHROMONE-2-AND-3-CARBOXYLICACIDS AND THEIR DERIVATIVES-G.P. Ellis and G. Barker 3 4-OXOPYRANOAZOLES AND 4-OXOPYRANOAZINES-Misbahul Ain Khan 4 ISOTOPE TECHNIQUES IN THE STUDY OF DRUG METABOLISM-Y. Kobayashi and D.V. Maudsley 5 THE PHARMACOTHERAPY OF PARKINSONISM-R.M. Pinder 6 ADRENOCHROME AND RELATED COMPOUNDS-R.A. Heacock and W.S. Powell VOLUME 10 1 MEDLARS COMPUTER INFORMATION RETRIEVAL-A.J. Hartley 2 THE USE OF ENZYMOLOGY IN PHARMACOLOGICAL AND TOXICOLOGICAL INVESTIGATIONS-W.G. Smith 3 THE METABOLISM AND BIOLOGICAL ACTIONS OF COUMARINS-G. Feuer 4 CARCINOGENICITY AND STRUCTURE IN POLYCYCLIC HYDRO- CARBONS-D.W. Jones and R.S. Matthews 5 LINEAR FREE ENERGY RELATIONSHIPS AND BIOLOGICAL ACTION-K.C. James 6 RECENT ADVANCES IN THE SYNTHESIS OF NITRILES-G.P. Ellis and I.L. Thomas '- VOLUME 11 1 STEREOCHEMICAL ASPECTS OF PARASYMPATHOMIMETICS AND THEIR ANTAGONISTS : RECENT DEVELOPMENTS-A.F. Casy 2 QUANTUM CHEMISTRY IN DRUG RESEARCH-W.G. Richards and M.E. Black 3 PSYCHOTOMIMETICS OF THE CONVOLVULACEAE-R.A. Heacock 4 ANTIHYPERLIPIDAEMIC AGENTS-E.C. Witte 5 THE MEDICINAL CHEMISTRY OF LITHIUM-E. Bailey, P.A. Bond, B.A. Brooks, M. Dimitrakoudi, F.D. Jenner, A. Judd, C.R. Lee, E.A. Lenton, S. McNeil, R.J. Pollitt, G.A. Sampson and E.A. Thompson ix VOLUME 12 I GAS-LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY IN BIOCHEMIS- TRY, PHARMACOLOGY AND TOXICOLOGY-A.M. Lawson and G.H. Draffan 2 RECENT ADVANCES IN COLUMN CHROMATOGRAPHY-K.W. Williams and R.C. Smith 3 NMR SPECTROSCOPY IN BIOLOGICAL SCIENCES-P.J. Sadler 4 ELECTRON SPIN RESONANCE IN MEDICINAL CHEMISTRY-D.L. Williams-Smith and S.J. Wyard 5 POLAROGRAPHY IN BIOCHEMISTRY, PHARMACOLOGY AND TOXI- COLOGY-M. Brezina and J. Volke 6 METHODS RELATED TO CYCLIC AMP AND ADENYLATE CYCLASE-B.G. Benfey 7 RESISTANCE OF PSEUDOMONAS AERUCINOSA TO ANTIMICROBIAL DRUGS-R.B. Sykes and A. Morris 8 FUNCTIONAL MODIFICATIONS AND NUCLEAR ANALOGUES OF 8-LACTAM ANTIBIOTICS-Part I-J.Cs. Jaszberenyi and T.E. Gunda VOLUME 13 1 CLINICAL ENZYMOLOGY-David M. Goldberg 2 THE RELEASE OF PHARMACOLOGICALLY ACTIVE SUBSTANCES IN PARASITIC INFECTIONS-P.F.L. Boreham and I.G. Wright 3 THE MEDICINAL CHEMISTRY OF I,2,3-TRIAZINES-Malcolm F.G. Stevens 4 THE BIOLOGICAL USES AND IMPORTANCE OF GLUTARALDEHYDE-A.D. Russell and D. Hopwood 5 THE CHEMISTRY AND BIOCHEMISTRY OF C-NUCLEOSIDES-G. Doyle Daves, Jr. and C.C. Cheng VOLUME 14 1 ASPECTS OF THE PHARMACOLOGY OF PASSIVE ION TRANSFER ACROSS CELL MEMBRANES-A.W. Cuthbert 2 THE BIO-MEDICAL AND RELATED ROLES OF ION-SELECTIVE MEMBRANE ELECTRODES-G.J. Moody and J.D.R. Thomas 3 BIOLOGICAL ACTIVITY OF POLYENE ANTIBIOTICS-S.M. Hammond 4 FUNCTIONAL MODIFICATIONS AND NUCLEAR ANALOGUES OF 8-LACTAM ANTIBIOTICS-PART 11-E.T. Gunda and J.Cs. Jaszberenyi 5 THE ROLE OF BIOGENIC AGENTS IN THE ACTIONS OF CENTRALLY-ACTING ANALGESICS-R.D.E. Sewell and P.S.J. Spencer 6 FLAVONOIDS : SOME PHYSIOLOGICAL AND NUTRITIONAL CONSIDER- ATIONS-R.E. Hughes and H.K. Wilson VOLUME 15 1 THE USE OF STABLE ISOTOPES IN MEDICINAL CHEMISTRY-D. Halliday 2 MEMBRANE-ACTIVE ANTIMICROBIAL AGENTS-P.A. Lambert 3 ADRIAMYCIN AND RELATED ANTHRACYCLINE ANTIBIOTICS-J.R. Brown 4 THE HYPOPHYSIOTROPHIC HORMONES-J.C. Buckingham 5 COPPER COMPLEXES-A UNIQUE CLASS OF ANTI-ARTHRITIC DRUGS-R.J.R. Sorenson 6 NON-TRICYCLIC ANTIDEPRESSANTS-J. van Dijk, J. Hartog and F.C. Hillen 7 THE CHEMISTRY .AND BIOLOGICAL ACTIVITY OF a-(N)-HETEROCYCLIC CARBOXALDEHYDE THIOSEMICARBAZONES-K.C. Agarwal and A.C. Sartorelli 8 PROSTAGLANDINS AND THROMBOXANES-M.P.L. Caton and K. Crowshaw X Progress in Medicinal Chemistry - Vol. 16, edited by G.P. Ellis and G.B. West 0Elsevier/North-Holland Biomedical Press - 1979 1 Recent Changes in Patent Law F. MURPHY, B.Sc., M.R.I.C.,C.P.A., E.P.A. Fisons Ltd., Ipswich, Suflolk IPl lQH, England INTRODUCTION 1 THE PURPOSE OF THE PATENT SYSTEM 3 EXAMINATION OF PATENT APPLICATIONS 4 TERRITORIAL JURISDICTION 5 INTERNATIONAL CO-OPERATION ON PATENT LAW 5 UNITED KINGDOM PATENTS ACT 1977 7 Patentable inventions 7 Novelty and inventiveness 10 Procedure for filing 12 Examination 15 Revocation 16 Fees 17 Other important changes 18 PATENTS IN OTHER COUNTRIES 20 Patentable inventions - Italy 23 Procedures for securing patents overseas 25 European patent convention 27 Patent cooperation treaty 32 CONCLUSION 33 REFERENCES 33 INTRODUCTION A number of major developments in the comparatively calm world of patents occurred in 1978. These included a new Patents Act in the United Kingdom, 2 RECENT CHANGES IN PATENT LAW the commencement of operation of the European Patent Office and the institution of operations under the Patent Cooperation Treaty. Additionally, in February 1978 an important decision of the Constitutional Court in Italy nullified Article 14 of the Italian Patents Act, which had prohibited the grant of patents for pharmaceuticals. These various developments have or will have a significant effect on the procedure for obtaining patents and the importance of patents both generally and particularly as regards pharmaceuticals.
Recommended publications
  • Compositions Comprising Drospirenone Molecularly
    (19) & (11) EP 1 748 756 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: A61K 9/00 (2006.01) A61K 9/107 (2006.01) 29.04.2009 Bulletin 2009/18 A61K 9/48 (2006.01) A61K 9/16 (2006.01) A61K 9/20 (2006.01) A61K 9/14 (2006.01) (2006.01) (2006.01) (21) Application number: 05708751.2 A61K 9/70 A61K 31/565 (22) Date of filing: 10.03.2005 (86) International application number: PCT/IB2005/000665 (87) International publication number: WO 2005/087194 (22.09.2005 Gazette 2005/38) (54) COMPOSITIONS COMPRISING DROSPIRENONE MOLECULARLY DISPERSED ZUSAMMENSETZUNGEN AUS DROSPIRENON IN MOLEKULARER DISPERSION DES COMPOSITIONS CONTENANT DROSPIRENONE A DISPERSION MOLECULAIRE (84) Designated Contracting States: (72) Inventors: AT BE BG CH CY CZ DE DK EE ES FI FR GB GR • FUNKE, Adrian HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR D-14055 Berlin (DE) Designated Extension States: • WAGNER, Torsten AL BA HR MK YU 13127 Berlin (DE) (30) Priority: 10.03.2004 EP 04075713 (74) Representative: Wagner, Kim 10.03.2004 US 551355 P Plougmann & Vingtoft a/s Sundkrogsgade 9 (43) Date of publication of application: P.O. Box 831 07.02.2007 Bulletin 2007/06 2100 Copenhagen Ø (DK) (60) Divisional application: (56) References cited: 08011577.7 / 1 980 242 EP-A- 1 260 225 EP-A- 1 380 301 WO-A-01/52857 WO-A-20/04022065 (73) Proprietor: Bayer Schering Pharma WO-A-20/04041289 US-A- 5 569 652 Aktiengesellschaft US-A- 5 656 622 US-A- 5 789 442 13353 Berlin (DE) Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations.
    [Show full text]
  • IJCB 42B(1) 166-172.Pdf
    Indian Journal of Chemistry Vol. 42B, January 2003, pp. 166-172 Synthesis and biological activity of 16-arylidene derivatives of estrone and estrone methyl ether Maninder Minu* & Dharam Paul lindal University In 5titutc of Pharmaceutical Sciences, Panjab University, Chandigarh 160014, India and G Leclercq & M Borras institut Jules Bordet, Association Hospitaliere de Bruxelles. Centre des Tumeurs de I'ULB, Rue Heger-Bordet 1- 1000, Belgiulll Received 24 April 200 I .. accepted (revised) 20 March 2002 The synthesis of 16-arylidene derivatives 3, 4, S, 6, 7. 8. 9, 10, 11, 12, 13, 14 and IS is described. These compounds have been tested at NCI, Bethesda, for their antineoplastic acti vity against the cell panel consisting of 60-ce!l lines and th e compounds 3, 4, S, 6 and 7 have also been tested for their ill vitro estrogenic / antiestrogenic activity; induction of ERE­ dependent luciferase inductio n was measured (MvLN celis). The formation of active steroids by aromatase has It was conceived that selective inhibitors of aroma­ been considered to play an important role in the de­ tase might be useful as a pharmacological tool to de­ velopment of human breast carcinoma t, at least one­ vice successful treatment approach for the hormonal third of all breast cancers establishing that. the estro­ dependent breast cancer. Our efforts were focused on gen-dependent carcinoma regresses following estro­ designing estrogen and estrogen methyl ether deriva­ 2 gen deprivation . In the postmenopausal women, the tives that might inhibit or possess antiestrogenic activ­ production of estrogen takes place in peripheral tissue ity. From these efforts, several 16-arylidine deriva­ 3 from inactive precursors by the action of aromatase .
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al
    US 200601 10428A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 de Juan et al. (43) Pub. Date: May 25, 2006 (54) METHODS AND DEVICES FOR THE Publication Classification TREATMENT OF OCULAR CONDITIONS (51) Int. Cl. (76) Inventors: Eugene de Juan, LaCanada, CA (US); A6F 2/00 (2006.01) Signe E. Varner, Los Angeles, CA (52) U.S. Cl. .............................................................. 424/427 (US); Laurie R. Lawin, New Brighton, MN (US) (57) ABSTRACT Correspondence Address: Featured is a method for instilling one or more bioactive SCOTT PRIBNOW agents into ocular tissue within an eye of a patient for the Kagan Binder, PLLC treatment of an ocular condition, the method comprising Suite 200 concurrently using at least two of the following bioactive 221 Main Street North agent delivery methods (A)-(C): Stillwater, MN 55082 (US) (A) implanting a Sustained release delivery device com (21) Appl. No.: 11/175,850 prising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more (22) Filed: Jul. 5, 2005 bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more Related U.S. Application Data bioactive agents Subretinally; and (60) Provisional application No. 60/585,236, filed on Jul. (C) instilling (e.g., injecting or delivering by ocular ion 2, 2004. Provisional application No. 60/669,701, filed tophoresis) one or more bioactive agents into the Vit on Apr. 8, 2005. reous humor of the eye. Patent Application Publication May 25, 2006 Sheet 1 of 22 US 2006/0110428A1 R 2 2 C.6 Fig.
    [Show full text]
  • Customs Tariff - Schedule
    CUSTOMS TARIFF - SCHEDULE 99 - i Chapter 99 SPECIAL CLASSIFICATION PROVISIONS - COMMERCIAL Notes. 1. The provisions of this Chapter are not subject to the rule of specificity in General Interpretative Rule 3 (a). 2. Goods which may be classified under the provisions of Chapter 99, if also eligible for classification under the provisions of Chapter 98, shall be classified in Chapter 98. 3. Goods may be classified under a tariff item in this Chapter and be entitled to the Most-Favoured-Nation Tariff or a preferential tariff rate of customs duty under this Chapter that applies to those goods according to the tariff treatment applicable to their country of origin only after classification under a tariff item in Chapters 1 to 97 has been determined and the conditions of any Chapter 99 provision and any applicable regulations or orders in relation thereto have been met. 4. The words and expressions used in this Chapter have the same meaning as in Chapters 1 to 97. Issued January 1, 2020 99 - 1 CUSTOMS TARIFF - SCHEDULE Tariff Unit of MFN Applicable SS Description of Goods Item Meas. Tariff Preferential Tariffs 9901.00.00 Articles and materials for use in the manufacture or repair of the Free CCCT, LDCT, GPT, UST, following to be employed in commercial fishing or the commercial MT, MUST, CIAT, CT, harvesting of marine plants: CRT, IT, NT, SLT, PT, COLT, JT, PAT, HNT, Artificial bait; KRT, CEUT, UAT, CPTPT: Free Carapace measures; Cordage, fishing lines (including marlines), rope and twine, of a circumference not exceeding 38 mm; Devices for keeping nets open; Fish hooks; Fishing nets and netting; Jiggers; Line floats; Lobster traps; Lures; Marker buoys of any material excluding wood; Net floats; Scallop drag nets; Spat collectors and collector holders; Swivels.
    [Show full text]
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
    [Show full text]
  • Part I Biopharmaceuticals
    1 Part I Biopharmaceuticals Translational Medicine: Molecular Pharmacology and Drug Discovery First Edition. Edited by Robert A. Meyers. © 2018 Wiley-VCH Verlag GmbH & Co. KGaA. Published 2018 by Wiley-VCH Verlag GmbH & Co. KGaA. 3 1 Analogs and Antagonists of Male Sex Hormones Robert W. Brueggemeier The Ohio State University, Division of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, Columbus, Ohio 43210, USA 1Introduction6 2 Historical 6 3 Endogenous Male Sex Hormones 7 3.1 Occurrence and Physiological Roles 7 3.2 Biosynthesis 8 3.3 Absorption and Distribution 12 3.4 Metabolism 13 3.4.1 Reductive Metabolism 14 3.4.2 Oxidative Metabolism 17 3.5 Mechanism of Action 19 4 Synthetic Androgens 24 4.1 Current Drugs on the Market 24 4.2 Therapeutic Uses and Bioassays 25 4.3 Structure–Activity Relationships for Steroidal Androgens 26 4.3.1 Early Modifications 26 4.3.2 Methylated Derivatives 26 4.3.3 Ester Derivatives 27 4.3.4 Halo Derivatives 27 4.3.5 Other Androgen Derivatives 28 4.3.6 Summary of Structure–Activity Relationships of Steroidal Androgens 28 4.4 Nonsteroidal Androgens, Selective Androgen Receptor Modulators (SARMs) 30 4.5 Absorption, Distribution, and Metabolism 31 4.6 Toxicities 32 Translational Medicine: Molecular Pharmacology and Drug Discovery First Edition. Edited by Robert A. Meyers. © 2018 Wiley-VCH Verlag GmbH & Co. KGaA. Published 2018 by Wiley-VCH Verlag GmbH & Co. KGaA. 4 Analogs and Antagonists of Male Sex Hormones 5 Anabolic Agents 32 5.1 Current Drugs on the Market 32 5.2 Therapeutic Uses and Bioassays
    [Show full text]
  • EURL GUIDANCE on SUBSTANCES INCLUDED in the SUBSTANCE CATEGORIES LISTED in ANNEX I of SANTE 2017/11987
    DRAFT 24 September 2019 (EURLs ANSES, BVL and WFSR) EURL GUIDANCE ON SUBSTANCES INCLUDED IN THE SUBSTANCE CATEGORIES LISTED IN ANNEX I of SANTE 2017/11987 1. A1a Stilbenes (EURL WFSR Wageningen) Cfr. Substances listed for Group A1 in the MMPR Guidance 2. A1b Antithyroid agents (EURL WFSR Wageningen) Cfr. Substances listed for Group A2 in the MMPR Guidance 3. A1c Steroids (EURL WFSR Wageningen) Cfr. Substances listed for Group A3 in the MMPR Guidance 17b-Testosterone (4-Androsten-17b-ol-3-one) 17a-Testosterone (4-Androsten-17a-ol-3-one) 17a-Boldenone 17b-Boldenone Clostebol (CLTb) (4-androsten-4-chloro-17ß-ol-3-one) CLAD (4-chloro-4-androst-3,17-dione) (chloorandrosteendion) a-Estradiol (17a-Estradiol) 17b-estradiol (17ß-estradiol) Methylboldenone (1,4-Androstadien-17a-methyl-17b-ol-3-one) 17a-Methyltestosterone (4-Androsten-17a-methyl-17b-ol-3-one) 17b-Nortestosterone (b-nandrolone) 17α-Nortestosterone (4-estren-17a-ol-3-one) Ethinylestradiol (EE2) 17a-Trenbolone 17b-Trenbolone 16b-hydroxy-stanozolol Megestrol Melengestrol Chlormadinone Medroxyprogesterone Progesterone (P1) (4-Pregnene-3,20-dione (Pregnen(4)-3,20-dione)) Androsten-17ß-ol-3-one [1,(5a)-] (17b-1-testosteron) Mestranol (Ethynylestradiol 3-methyl ether) Fluoxymesterone (FMT) (4-androsten-9a-fluoro-17a-methyl-11ß,17ß-diol-3-one) DHEA (5-androsten-3b-ol-17-one) ethyl-5ß-estrane-3a,17ß-diol [17α-] (EED) Exemestane (6-Methyleneandrosta-1,4-diene-3,17-dione) Mesterolone (Androviron) Dromostanolone (Drostanolone) 2a-Methyl-5a-androstan-3a-ol-17-one
    [Show full text]
  • PHARMACEUTICAL APPENDIX to the TARIFF SCHEDULE 2 Table 1
    Harmonized Tariff Schedule of the United States (2020) Revision 19 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2020) Revision 19 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names INN which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service CAS registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known.
    [Show full text]
  • Rocuronium Bromide PRODUCT DATA SHEET Issue Date 01/06/2020
    Rocuronium Bromide PRODUCT DATA SHEET issue date 01/06/2020 Product Name: Rocuronium Bromide Product Number: R045 CAS Number: 119302-91-9 Molecular Formula: C32H53BrN2O4 Molecular Weight: 609.68 Form: Powder Appearance: Off-white to yellowish powder Solubility: Soluble in water, ethanol, and DMSO. Source: Synthetic Storage Conditions: ≤30°C Description: Rocuronium Bromide is the bromide salt form of Rocuronium, a fumarate, aminosteroid type non-depolarizing neuromuscular blocking agent that relaxes the skeletal muscle. It was introduced in 1994, and has a similar pharmacokinetic profile to Vecuronium, as it is a derivative of the 3-hydroxy metabolite of Vecuronium. It competes with acetylcholine in binding to cholinergic receptors at neuromuscular junctions. Rocuronium Bromide is soluble in water, ethanol, and DMSO. Mechanism of Action: Rocuronium Bromide competes with acetylcholine and binds to cholinergic receptors at neuromuscular junctions. It binds to nicotinic receptors in the neuromuscular junction. It is classified as a neuromuscular nondepolarizing agent since it does not cause depolarization of the motor end plate. References: Anzenbacherova et al (2015) Interaction of Rocuronium with human liver cytochromes P450. J. Pharmacol. Sci. 127(2):190-195 PMID 25727956 Cembala TM, Sherwin JD, Tidmarsh MD, Appadu BL and Lambert DG (1998) Interaction of neuromuscular blocking drugs with recombinant human m1-m5 muscarinic receptors expressed in Chinese hamster ovary cells. B. J. Pharmacol. 125(5):1088-1094 PMID 9846649 Koksal PM and Gürbüzel M(2015) Analysis of genotoxic activity of ketamine and Rocuronium Bromide using the somatic mutation and recombination test in Drosophila melanogaster. Environ Toxicol Pharmacol. 39(2):628-634 PMID 25682000 Sauer et al (2017) Rocuronium is more hepatotoxic than succinylcholine in vitro.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness Et Al
    USOO6264,917B1 (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness et al. (45) Date of Patent: Jul. 24, 2001 (54) TARGETED ULTRASOUND CONTRAST 5,733,572 3/1998 Unger et al.. AGENTS 5,780,010 7/1998 Lanza et al. 5,846,517 12/1998 Unger .................................. 424/9.52 (75) Inventors: Jo Klaveness; Pál Rongved; Dagfinn 5,849,727 12/1998 Porter et al. ......................... 514/156 Lovhaug, all of Oslo (NO) 5,910,300 6/1999 Tournier et al. .................... 424/9.34 FOREIGN PATENT DOCUMENTS (73) Assignee: Nycomed Imaging AS, Oslo (NO) 2 145 SOS 4/1994 (CA). (*) Notice: Subject to any disclaimer, the term of this 19 626 530 1/1998 (DE). patent is extended or adjusted under 35 O 727 225 8/1996 (EP). U.S.C. 154(b) by 0 days. WO91/15244 10/1991 (WO). WO 93/20802 10/1993 (WO). WO 94/07539 4/1994 (WO). (21) Appl. No.: 08/958,993 WO 94/28873 12/1994 (WO). WO 94/28874 12/1994 (WO). (22) Filed: Oct. 28, 1997 WO95/03356 2/1995 (WO). WO95/03357 2/1995 (WO). Related U.S. Application Data WO95/07072 3/1995 (WO). (60) Provisional application No. 60/049.264, filed on Jun. 7, WO95/15118 6/1995 (WO). 1997, provisional application No. 60/049,265, filed on Jun. WO 96/39149 12/1996 (WO). 7, 1997, and provisional application No. 60/049.268, filed WO 96/40277 12/1996 (WO). on Jun. 7, 1997. WO 96/40285 12/1996 (WO). (30) Foreign Application Priority Data WO 96/41647 12/1996 (WO).
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0024365A1 Vaya Et Al
    US 2006.0024.365A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0024365A1 Vaya et al. (43) Pub. Date: Feb. 2, 2006 (54) NOVEL DOSAGE FORM (30) Foreign Application Priority Data (76) Inventors: Navin Vaya, Gujarat (IN); Rajesh Aug. 5, 2002 (IN)................................. 699/MUM/2002 Singh Karan, Gujarat (IN); Sunil Aug. 5, 2002 (IN). ... 697/MUM/2002 Sadanand, Gujarat (IN); Vinod Kumar Jan. 22, 2003 (IN)................................... 80/MUM/2003 Gupta, Gujarat (IN) Jan. 22, 2003 (IN)................................... 82/MUM/2003 Correspondence Address: Publication Classification HEDMAN & COSTIGAN P.C. (51) Int. Cl. 1185 AVENUE OF THE AMERICAS A6IK 9/22 (2006.01) NEW YORK, NY 10036 (US) (52) U.S. Cl. .............................................................. 424/468 (22) Filed: May 19, 2005 A dosage form comprising of a high dose, high Solubility active ingredient as modified release and a low dose active ingredient as immediate release where the weight ratio of Related U.S. Application Data immediate release active ingredient and modified release active ingredient is from 1:10 to 1:15000 and the weight of (63) Continuation-in-part of application No. 10/630,446, modified release active ingredient per unit is from 500 mg to filed on Jul. 29, 2003. 1500 mg, a process for preparing the dosage form. Patent Application Publication Feb. 2, 2006 Sheet 1 of 10 US 2006/0024.365A1 FIGURE 1 FIGURE 2 FIGURE 3 Patent Application Publication Feb. 2, 2006 Sheet 2 of 10 US 2006/0024.365A1 FIGURE 4 (a) 7 FIGURE 4 (b) Patent Application Publication Feb. 2, 2006 Sheet 3 of 10 US 2006/0024.365 A1 FIGURE 5 100 ov -- 60 40 20 C 2 4.
    [Show full text]
  • Ovid MEDLINE(R)
    Supplementary material BMJ Open Ovid MEDLINE(R) and Epub Ahead of Print, In-Process & Other Non-Indexed Citations and Daily <1946 to September 16, 2019> # Searches Results 1 exp Hypertension/ 247434 2 hypertens*.tw,kf. 420857 3 ((high* or elevat* or greater* or control*) adj4 (blood or systolic or diastolic) adj4 68657 pressure*).tw,kf. 4 1 or 2 or 3 501365 5 Sex Characteristics/ 52287 6 Sex/ 7632 7 Sex ratio/ 9049 8 Sex Factors/ 254781 9 ((sex* or gender* or man or men or male* or woman or women or female*) adj3 336361 (difference* or different or characteristic* or ratio* or factor* or imbalanc* or issue* or specific* or disparit* or dependen* or dimorphism* or gap or gaps or influenc* or discrepan* or distribut* or composition*)).tw,kf. 10 or/5-9 559186 11 4 and 10 24653 12 exp Antihypertensive Agents/ 254343 13 (antihypertensiv* or anti-hypertensiv* or ((anti?hyperten* or anti-hyperten*) adj5 52111 (therap* or treat* or effective*))).tw,kf. 14 Calcium Channel Blockers/ 36287 15 (calcium adj2 (channel* or exogenous*) adj2 (block* or inhibitor* or 20534 antagonist*)).tw,kf. 16 (agatoxin or amlodipine or anipamil or aranidipine or atagabalin or azelnidipine or 86627 azidodiltiazem or azidopamil or azidopine or belfosdil or benidipine or bepridil or brinazarone or calciseptine or caroverine or cilnidipine or clentiazem or clevidipine or columbianadin or conotoxin or cronidipine or darodipine or deacetyl n nordiltiazem or deacetyl n o dinordiltiazem or deacetyl o nordiltiazem or deacetyldiltiazem or dealkylnorverapamil or dealkylverapamil
    [Show full text]